Finasteride, Pharmacogenomics, and Suicide Risk: a Public Health Concern

Epidmiological Signals and Clinical Concerns: The strongest clinical evidence to date comes from cohort studies comparing finasteride to similar agents like dutasteride. In a 2023 nationwide study, Laanani et al. reported no increased risk of suicidal behaviour in the general population of men treated for BPH with finasteride, relative to those treated with dutasteride—particularly among […]

An (Ir)reversible Affection of the Sexual Sphere: A Case Report

An (Ir)reversible Affection of the Sexual Sphere: A Case Report A 26-year-old man, otherwise healthy and without relevant medical history, began treatment with finasteride 1 mg for AGA. The treatment was discontinued after six months due to the development of genital hypesthesia and reduced ejaculatory potency, accompanied by a significant loss of sexual pleasure. Subsequently, […]

Ischemic Stroke in a Young Adult Male During Finasteride Therapy

A 20-year-old previously healthy male developed an acute left-sided headache lasting several minutes, followed by sudden generalized weakness and collapse. Symptoms resolved spontaneously within minutes and he resumed normal daily activities without seeking medical attention. The following morning, he awoke having persistent right-sided hemiparesis with predominant weakness of the right hand and dysarthria. Expecting spontaneous […]

Failing Public Health Again? Analytical Review of Depression and Suicidality From Finasteride

Finasteride…has long been suspected of causing severe neuropsychiatric reactions, including depression, anxiety, and suicidality… Concerns about depression from finasteride were raised in several studies as early as 2002. Between the years 2017 and 2023, 4 independent analyses of adverse event reporting systems and 4 studies using data mining of healthcare records indicated a significant increase […]

Finasteride-Induced Neuropsychiatric Reactions

Finasteride-induced depression results in billions of dollars lost in productivity worldwide each year. These external costs, borne by third parties who cannot mitigate them, represent a market failure that should be addressed through regulation. Finasteride for hair loss would probably not receive approval today, and its marketing should now be halted under the precautionary principle. […]

Systematic Review: 5α-Reductase Isoenzymes: From Neurosteroid Biosynthesis to Neuropsychiatric Outcomes

The inhibition of 5α-R represents a paradigmatic example of how a drug originally designed for urological and dermatological purposes may have repercussions for neurobiology and mental health. The available evidence suggests that while most patients tolerate finasteride and dutasteride adequately, there is a vulnerable subgroup in which a reduction in neurosteroids—particularly allopregnanolone—may contribute to the […]

Finasteride Withdrawal Induces Anxiety-like Behavior and Novelty Avoidance in Adult Male Rats

Our findings demonstrate that subchronic finasteride treatment in adult male rats induces distinct time-dependent behavioral changes. While the immediate effects observed after 20 days of treatment (i.e., T0) were modest, significant behavioral alterations became evident  month after drug discontinuation (i.e., T1). These withdrawal effects included pronounced hyperactivity, reduced center exploration in the open field, and marked […]

Isolated Depressive Disorders and Suicidality with Finasteride Use for Androgenetic Alopecia: A Call for Enhanced Vigilance

While adverse psychiatric drug reactions, including depressive symptoms and suicidality, are often reported in conjunction with sexual dysfunction, this study highlights the severity of depressive effects associated with finasteride, particularly the risk of suicidality even in the absence of associated sexual dysfunction or psychiatric history. The persistence of depressive symptoms sometimes beyond 20 months post-discontinuation, […]

Finasteride Use: Evaluation of Depression and Suicide Risk

Multiple clinical studies suggest that oral finasteride treatment may increase the risk of neuropsychiatric side effects. A systematic review found that the odds of developing depressive symptoms were significantly higher in oral finasteride users compared to non-users, with an odds ratio of 2.14. The pooled rates of depressive symptoms were higher with oral finasteride at […]

Association between Finasteride with Subjective Memory Deficits: A Study from the NHANES and FAERS Databases

Convergent evidence from both epidemiological studies and pharmacovigilance surveillance suggests a potential association between finasteride administration and cognitive dysfunction, particularly in memory-related domains. These findings underscore the need for comprehensive risk communication strategies regarding potential neurocognitive adverse effects during clinical consultations and for establishing routine cognitive monitoring protocols for patients undergoing prolonged finasteride therapy. Zhang […]